FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation

Roche announced today that the US Food and Drug Administration (FDA) has approved Lucentis ® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation (mCNV), a complication of severe near-sightedness that can lead to blindness.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news